ActiveCare®
SAFE DVT PREVENTION

ActiveCare+S.F.T.®
SYNCHRONIZED FLOW TECHNOLOGY

THE ONLY PROVEN MONOTHERAPY FOR DVT PREVENTION WITH NO MAJOR BLEEDING COMPLICATIONS FROM HOSPITAL TO HOME
As the only Proven Noninvasive Alternative to Drugs, ActiveCare+S.F.T.® Offers you Significant Benefits in the Prevention of DVT / VTE

- **Monotherapy Treatment** ActiveCare+S.F.T.® is the only device that provides supporting data, enabling the surgeon to make an informed decision based on the patient risk and DVT prevention protocol.

- **Reduced Bleeding Risk** ActiveCare+S.F.T.® is the only proven monotherapy for DVT prevention with no major bleeding complications.³

- **3 Times Better in VTE Prevention** The replacement of standard IPC by ActiveCare+S.F.T.® significantly reduces the VTE rate (70% risk reduction).⁴

- **Synchronized Flow Technology (S.F.T.®)** Unlike conventional IPC, S.F.T. applies gentle compression to the legs and synchronizes compression with the naturally-occurring respiratory venous flow rhythm of each patient, both contributing to maximum blood circulation.

- **From Hospital to Home** ActiveCare+S.F.T.® is small and portable allowing patient mobility and 24-hour preventative therapy.

- **Monitors Patient Compliance** ActiveCare+S.F.T.® is the only device that routinely monitors patient compliance, providing patients, caregivers and physicians with real-time information. A built-in LCD screen provides patient compliance and troubleshooting information.

- **Reduces Costly Readmissions** ActiveCare+S.F.T.® is an economically viable DVT prevention therapy. The device significantly reduces the drugs requirements and as such minimize the occurrence of major bleeding complications and the need for supplementary blood products that may lead to costly readmissions.

**ACCP 2012 Recommendation for Monotherapy DVT Prevention in THA, TKA and HF Surgery**

“... we recommend the use of only portable battery-operated IPCDs capable of recording and reporting proper wear time on a daily basis for inpatient and outpatient.”
Data to Back You, Guidelines to Support You

Efficacy
At least as good as any of the leading drugs in the market.\textsuperscript{2}

Use of the mobile compression device with or without aspirin for patients undergoing arthroplasty of a lower-extremity joint provides a noninferior risk for the development of venous thromboembolism compared with current pharmacological protocols.”\textsuperscript{1}

Superior Safety
The only proven monotherapy for DVT prevention with no major bleeding complications.\textsuperscript{3}


CUT THE RISK
SOLVE THE DVT / MAJOR BLEEDING DILEMMA